Wells Fargo
VVOS icon

Wells Fargo’s Vivos Therapeutics VVOS Stock Holding History

Wells Fargo’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-7
Closed -$34 – 7513
2024
Q1 		$34 Hold
7
– – ﹤0.01% 6950
2023
Q4 		$87 Buy
7
+1
+17% +$9 ﹤0.01% 6805
2023
Q3 		$30 Hold
6
– – ﹤0.01% 7071
2023
Q2 		$81 Buy
6
+1
+20% +$10 ﹤0.01% 6922
2023
Q1 		$44 Hold
5
– – ﹤0.01% 7143
2022
Q4 		$47 Hold
5
– – ﹤0.01% 7031
2022
Q3 		$0 Hold
5
– – ﹤0.01% 7458
2022
Q2 		$0 Buy
5
+1
+25% +$42 ﹤0.01% 7584
2022
Q1 		$0 Sell
4
-80
-95% -$5.23K ﹤0.01% 7908
2021
Q4 		$5K Hold
84
– – ﹤0.01% 6715
2021
Q3 		$8K Buy
84
+82
+4,100% +$8.62K ﹤0.01% 6279
2021
Q2 		$0 Buy
2
+1
+100% +$163 ﹤0.01% 7507
2021
Q1 		$0 Buy
+1
New +$179 ﹤0.01% 7437

Other funds holding VVOS

SWIG
Strategic Wealth Investment Group Louisville, Kentucky $788M AUM 14.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TWP
Triad Wealth Partners Lawrence, Kansas $1.26B AUM 17.86% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
S
SignatureFD Atlanta, Georgia $6.53B AUM 20.48% 1-Year Est. Return

Wells Fargo's VVOS Position: Q2 2024 in Review

Wells Fargo sold out of Vivos Therapeutics (VVOS) in Q2 2024, closing a stake of 7 shares — an estimated $34 sold.

Wells Fargo first reported a position in VVOS in Q1 2021 and held it in 13 quarters. The position peaked at $8K in Q3 2021. 19 funds tracked by Wall St. Rank hold VVOS as of Q2 2024.

  • Wells Fargo reported no remaining Vivos Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Wells Fargo sold 7 Vivos Therapeutics shares in Q2 2024, an estimated $34.
  • Wells Fargo first reported a position in Vivos Therapeutics in Q1 2021 and held it in 13 quarters.
  • Wells Fargo's Vivos Therapeutics position peaked at $8K in Q3 2021.
  • 19 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q2 2024.

Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.